AI Platform Could Speed Peptide Drug Discovery | Penn Engineering

Penn Engineers have released PeptiVerse, an open-source AI platform that predicts key chemical and biological properties of peptides—such as solubility, cell entry, toxicity, and bioavailability—in a single accessible web interface. The tool consolidates fragmented datasets and lets researchers screen peptide candidates before costly synthesis, addressing a critical bottleneck in peptide drug discovery accelerated by GLP-1 success.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.